Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies operating in every region of the globe. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). We have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.
Driven by our commitment to patients, we strive to develop strong relationships with patient communities and listen to their perspectives so that we can truly understand their needs. These collaborations guide us as we continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before.
Genzyme is...Life-changing. Family. Hope. Driven. Committed. Selfless. These are just a few of the words that 14 employees from around the world used to describe Genzyme. In the video, these employees share their personal perspectives and experiences, capturing the unique spirit that drives both individual.
Genzyme's Therapeutic Areas
Genzyme is structured into two therapeutics areas organized around our core medical areas:
Regardless of disease area or size of the patient community, our approach is to provide personalized care by truly understanding patients’ needs. This special approach is evident across the company and in both of our therapeutic areas.